Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL

NCT03704714 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03704714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03704714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Lead sponsor
Northwestern University
Phase
Phase 1/2
Overall status
Suspended
Start date
November 20, 2018
Completion date
June 11, 2025
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, b-cell non-hodgkin lymphoma, cd20 positive, diffuse large b-cell lymphoma unclassifiable, intravascular large b-cell lymphoma, primary mediastinal (thymic) large b-cell lymphoma, t-cell/histiocyte-rich large b-cell lymphoma, transformed follicular lymphoma to diffuse large b-cell lymphoma